Patents by Inventor Sanjiv Sur

Sanjiv Sur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions related to recombinant NEIL2
    Patent number: 11851464
    Abstract: Certain embodiments are directed to NEIL2 compositions and method of using NEIL2 composition to treat subjects in need of such treatment.
    Type: Grant
    Filed: April 11, 2022
    Date of Patent: December 26, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Tapas Hazra, Sanjiv Sur, Ashok Chopra
  • METHODS AND COMPOSITIONS RELATED TO RECOMBINANT NEIL2
    Publication number: 20220259274
    Abstract: Certain embodiments are directed to NEIL2 compositions and method of using NEIL2 composition to treat subjects in need of such treatment.
    Type: Application
    Filed: April 11, 2022
    Publication date: August 18, 2022
    Inventors: Tapas HAZRA, Sanjiv SUR, Ashok CHOPRA
  • BRD4 inhibitor treatment of IgE-mediated diseases
    Patent number: 11389433
    Abstract: Certain embodiments are directed to methods of using BRD4 inhibitors for treating IgE-mediated diseases.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: July 19, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Allan Brasier, Sanjiv Sur, Jia Zhou, Bing Tian
  • METHODS AND COMPOSITIONS RELATED TO RECOMBINANT NEIL2
    Publication number: 20200102358
    Abstract: Certain embodiments are directed to NEIL2 compositions and method of using NEIL2 composition to treat subjects in need of such treatment.
    Type: Application
    Filed: September 27, 2019
    Publication date: April 2, 2020
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Tapas HAZRA, Sanjiv SUR, Ashok CHOPRA
  • BRD4 INHIBITOR TREATMENT OF IGE-MEDIATED DISEASES
    Publication number: 20190381013
    Abstract: Certain embodiments are directed to methods of using BRD4 inhibitors for treating IgE-mediated diseases.
    Type: Application
    Filed: June 18, 2019
    Publication date: December 19, 2019
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Allan Brasier, Sanjiv Sur, Jia Zhou, Bing Tian
  • METHODS FOR TREATING ALLERGIC AIRWAY INFLAMMATION
    Publication number: 20160311911
    Abstract: Provided herein are methods for treating a symptom and/or clinical sign associated with an allergy that includes neutrophil recruitment, such as allergic airway inflammation. In one embodiment, the method includes administering to a subject a composition that includes a CXCR2 inhibitor, a MD2 inhibitor, a MyD88 inhibitor, or a combination thereof. The subject can have an allergy that includes neutrophil recruitment such as allergic airway inflammation, or be at risk of an allergy that includes neutrophil recruitment such as an allergic airway inflammation.
    Type: Application
    Filed: April 22, 2016
    Publication date: October 27, 2016
    Inventors: Sanjiv Sur, Istvan Boldogh
  • Methods for inhibiting allergic inflammation and other responses initiated by pollens, molds, and other non-animal derived allergens
    Publication number: 20060198904
    Abstract: Disclosed are methods for treating or preventing allergic inflammation in a subject and methods for treating or preventing one or more symptoms of allergic inflammation in a subject. The methods include administering to the subject a compound which inhibits reactive oxygen species. Also disclosed are methods for reducing a non-animal-derived allergen's ability to initiate an allergenic process and for reducing prooxidant activity of a non-animal-derived allergen. The methods include contacting the non-animal-derived allergen with an agent which inhibits reactive oxygen species. Methods for screening a compound for its usefulness as an agent for reducing a non-animal-derived allergen's ability to initiate an allergenic process and/or for its usefulness as a therapeutic agent for treating or preventing allergic inflammation and/or the symptoms associated therewith are also disclosed.
    Type: Application
    Filed: November 20, 2003
    Publication date: September 7, 2006
    Inventors: Istvan Boldogh, Sanjiv Sur